The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

Publication Type:

Journal Article

Source:

The Journal of antimicrobial chemotherapy, Volume 67, Issue 3, p.715-22 (2012)

Keywords:

2012, April 2012, Vaccine and Infectious Disease Division

Abstract:

Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted.